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Abstract
Although in vitro screens are essential for the initial identification of candidate therapeutic agents, a rigorous assessment of the drug's ability to
inhibit tumor growth must be performed in a suitable animal model. The type of animal model that is best for this purpose is a topic of intense
discussion. Some evidence indicates that preclinical trials examining drug effects on tumors arising in transgenic mice are more predictive of
clinical outcome1and so candidate therapeutic agents are often tested in these models. Unfortunately, transgenic models are not available for
many tumor types. Further, transgenic models often have other limitations such as concerns as to how well the mouse tumor models its human
counterpart, incomplete penetrance of the tumor phenotype and an inability to predict when tumors will develop.
Consequently, many investigators use xenograft models (human tumor cells grafted into immunodeficient mice) for preclinical trials if appropriate
transgenic tumor models are not available. Even if transgenic models are available, they are often partnered with xenograft models as the latter
facilitate rapid determination of therapeutic ranges. Further, this partnership allows a comparison of the effectiveness of the agent in transgenic
tumors and genuine human tumor cells. Historically, xenografting has often been performed by injecting tumor cells subcutaneously (ectopic
xenografts). This technique is rapid and reproducible, relatively inexpensive and allows continuous quantitation of tumor growth during the
therapeutic period2. However, the subcutaneous space is not the normal microenvironment for most neoplasms and so results obtained with
ectopic xenografting can be misleading due to factors such as an absence of organ-specific expression of host tissue and tumor genes. It has
thus been strongly recommended that ectopic grafting studies be replaced or complemented by studies in which human tumor cells are grafted
into their tissue of origin (orthotopic xenografting)2. Unfortunately, implementation of this recommendation is often thwarted by the fact that
orthotopic xenografting methodologies have not yet been developed for many tumor types.
Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive sarcomas that occur sporadically or in association with
neurofibromatosis type 13and most commonly arise in the sciatic nerve4. Here we describe a technically straightforward method in which firefly
luciferase-tagged human MPNST cells are orthopically xenografted into the sciatic nerve of immunodeficient mice. Our approach to assessing the
success of the grafting procedure in individual animals and subsequent non-biased randomization into study groups is also discussed.
Protocol
1. Initial Preparation of Non-nude Immunodeficient Mice (not Necessary for Nude Strains):
2. Preparation of MPNST Cells for Injection on the Day of Grafting
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1. All procedures were reviewed and approved in advance by the UAB Institutional Animal Care and Use Committee and conducted by properly
trained personnel. We have successfully used three strains of immunodeficient mice for these experiments: a) Foxchase outbred SCID mice
(CB17/lcr-Prkdcscid/lcrCrl mice); b) NIH III mice (NIHS-LystbgFoxn1nuBrkxid mice); and c) NOD-SCIDγ mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
mice). In our hands, the growth of orthotopic xenografts is virtually identical in NIH III and NOD-SCIDγ mice, both of which carry mutations
affecting the function of T cells, B cells and NK cells; for this protocol, the number of days required for graft growth, the time at which therapy
is initiated and the times post-grafting when imaging is performed are those we have empirically determined using NOD-SCIDγ mice. Graft
growth in Foxchase outbred SCID mice, which have defects in T- and B-cell function, typically takes longer.
2. To facilitate grafting of large numbers of non-nude immunodeficient mice, we remove hair from the surgical site on the afternoon prior to
grafting. Mice are anesthetized using an isoflurane induction chamber attached to a vaporizer with scavenge for the waste gas. To maintain
body temperature, animals are handled on a heating pad throughout this process. Clippers are used to remove hair from the mid-back down
to the knee of the hind leg on the side which is to be grafted. Any remaining hair is carefully removed from the site in ~5 minutes using a
chemical depilatory agent (e.g. Nair, in particular a product with aloe vera for sensitive skin). Removal of the depilatory product is
recommended as it can lead to irritation of the skin, eyes, and other body surfaces to which it might spread. We do not graft both sciatic
nerves in these experiments as this may bilaterally impair hindleg function, resulting in the loss of mice from the study groups.
3. Mice are allowed to fully recover on a heating pad in an isolation cage without bedding; this both ensures that the mice are not injured by
other, more fully alert animals and prevents them from accidentally inhaling bedding. When mice are fully mobile and show no evidence of
grogginess, they can be reintroduced into a cage with other mice.
1. In this protocol, the specific numbers of cells grafted and the times required for tumor growth post-grafting are those we have empirically
determined for ST88-14 cells, a commonly used MPNST line that was derived from an NF1-associated tumor5. The cells we use for grafting
have been transduced with a lentiviral vector containing a CMV-luciferase-IRES-puromycin cassette and clones stably expressing firefly
luciferase identified by bioluminescence imaging6. We have also performed grafting experiments with MPNST cells stably transfected with3. Grafting Protocol
4. Assessment of Graft Success and Randomization Into Study Groups
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plasmids expressing firefly luciferase under the control of the CMV immediate early promoter. We do not recommend this as we have found
that these plasmid vectors are prone to undergo extinction of expression following grafting.
2. ST88-14 cells are grown in Dulbecco's minimal essential medium supplemented with 10% fetal calf serum, 10 μg/mL streptomycin and 10
IU/mL penicillin (DMEM10); 5 μg/ml puromycin is also included to maintain selection for the lentiviral vector. We have maintained these cells
in our laboratory for 50 passages and have not observed any variation in cell growth in any of these passages. 9 x 105 ST88-14 cells are
plated in a T175 flask and grown for 3 days, at which point the flask is approximately 80% confluent. To graft 35 mice, a single 80% confluent
T175 flask is required; at this density, our average yield for ST88-14 cells is 7.3 x 106 cells per T175 flask. It is critically important that the cells
not be allowed to grow to confluence prior to harvesting for grafting. We have found that grafting cells harvested from confluent flasks results
in a higher degree of graft failure and often prolongs the in vivo course of graft growth.
3. ST88-14 cells are rinsed once with room temperature Hanks' balanced salt solution. Cells are removed from the flask using Cell Stripper cell
dissociation solution for 30 seconds to 1 minute at room temperature. Five milliliters of DMEM10 (Note: puromycin is not included in this
medium) per each milliliter of Cell Stripper used are then added to the cells.
4. Cells are counted using a hemocytometer. 5 x 103 ST88-14 cells suspended in 3 μL will be injected per mouse. A quantity of cells sufficient to
graft the entire cohort, with allowance for pipetting error (e.g., for 35 mice, we typically transfer a number of cells sufficient to graft 40 mice), is
transferred into a sterile 1.5 mL tube. The cells are centrifuged at 3000 rpm for 5 minutes. The supernatant is carefully removed and the cell
pellet resuspended in DMEM10 (Note: puromycin is not included in this medium) to a final concentration of 5 x 103 cells per 3 μL. Keep the
cells on ice.
1. Mice are anesthetized in the induction chamber of an isoflurane vaporizer until they no longer withdraw their hindlimb to a toe pinch stimulus.
Mice are placed on their side and injected subcutaneously with 0.05 mg/kg of buprenorphine hydrocholoride. Anesthesia is then maintained
via continuous administration of isoflurane delivered via nose-cone. Please note that a euthanized mice was used to demonstrate this
procedure for the video; consequently, the isoflurane tubing used to deliver isoflurane is not visible in the video.
2. To maintain body temperature, animals are handled on a heating pad throughout the grafting process. To prevent corneal desiccation, a small
drop of ophthalmic ointment (Puralube veterinary ointment) is administered to each eye. As it will be necessary for each mouse to be uniquely
identified throughout the trial, an ear tag with a unique identifier number is clipped to the right ear of each mouse.
3. Place animal on stomach, spreading hind legs. Cover the mouse with a sterile drape, exposing the surgical window (flank) where grafting will
occur. The sterile drape should allow visualization of the head, both to ensure that the nose is still inside the cone and to allow monitoring of
respiration and the animal's color. Apply betadine to the surgical site with a cotton tipped applicator, starting in the center of the flank and
gradually spiraling outward to the edges of the surgical window. 70% ethanol is then applied to the surgical site in the same manner.
Consecutive applications of betadine followed by ethanol are repeated twice more.
4. Remove cells from ice and either gently vortex or flick the tube to resuspend settled cells. Using a pipette, remove 3.2 μL of the cell
suspension and eject it onto a piece of Parafilm. By removing more than is needed and placing the suspension on Parafilm, we can ensure
that there are no bubbles in the suspension and that we have a full 3 μL for the injection. Pull as much of the cell suspension possible into a
10 μL Hamilton syringe equipped with a 33 gauge needle. Flick bubbles from the syringe and expel the excess cell suspension to exactly 3
μL. Hold the cells and the cell-containing syringe on ice until ready to use; to ensure that the needle remains sterile, do not allow contact with
the ice or the bucket. A piece of saran wrap can be placed on top of the ice to the syringe from directly contacting the ice.
5. Using a No. 4 scalpel handle equipped with a No. 22 scalpel blade, make an incision through the skin of the flank just below and parallel to
the femur; make sure that the incision does not extend beyond the limits of the surgically scrubbed field. Open the skin incision with a surgical
clamp or manually to expose the underlying muscle. A fascial plane will be visible running along the length of the leg; the sciatic nerve lies
beneath this and between the two muscles connected by the fascia. Using a pair of sharp-tipped scissors, blunt dissect through this fascia to
expose the sciatic nerve, which should be apparent as a white linear structure about the thickness of a thick thread.
6. Using a pair of sharp-tipped curved forceps, carefully dissect under the nerve, loosening it from the underlying muscle; this both elevates and
isolates the nerve. Leave the forceps under the nerve to maintain this position. Carefully insert the needle of the Hamilton syringe into the
nerve, trying to maintain the angle of injection as parallel with the nerve as possible so the needle does not puncture through the underside of
the nerve. The needle should be inserted towards the end of the nerve distal to the spine-we have found that injection of tumor cells into the
nerve towards the spinal cord establishes the grafted tumor cells in closer proximity to the spinal cord. When this occurs, the tumor cells often
invade the spinal cord, resulting in premature loss of the animal from the study group due to compromise of spinal cord function.
7. Once the needle is properly positioned in the nerve, relax the tension produced in the nerve by the forceps and slowly inject cells from the
syringe into the nerve over 45-60 seconds. It is essential that this be done slowly as rapidly expulsion of the syringe contents will result in a
"back-wash" of tumor cells around the injection site and their loss. After all cells have been successfully injected, slowly withdraw the needle
to minimize loss of injected material.
8. Remove the forceps and carefully place nerve back into its original location under the muscle. Close the surgical incision with Vetbond
surgical glue. Hold incision together with forceps for approximately 20 seconds to allow the glue to dry.
9. The mouse is removed from the isoflurane nose-cone and placed alone in a bedding-free cage to recover. This cage should be kept on the
top of a heating pad until the animal has fully recovered. Part of the recovery cage should not be on a heating pad, this allows the animal to
move away from the heat if they get too warm. Following grafting, the animals should be assessed regularly for chewing at the site, lameness
or anorexia; these signs could indicate the animal is still in pain and that proper analgesics should be given. After gaining experience with this
procedure, we have found that 30-40 mice can readily be grafted in a single day.
1. Bioluminescence imaging is used to assess the success of the grafting procedure. We use an IVIS-100 system (originally from Xenogen,
which is now known as Calipers Inc.) to detect light emission from tumor-expressed firefly luciferase that is produced as a result of the
chemical reaction of luciferase with its substrate, D-Luciferin. Analyses of these images determine whether specific grafted mice are suitable
for entry into the therapeutic trial cohorts. In preliminary experiments, we have quantified the bioluminescence signals detectable, sacrificed
grafted mice, harvested their tumors and correlated tumor weights with the bioluminescence signals from region of interest analyses using the
manufacturer's Living Image Software. These studies demonstrated that there was a linear correlation between tumor graft weights and
bioluminescence light emission, indicating that bioluminescence imaging is an appropriate surrogate means of assessing xenograft growth
throughout the course of preclinical trials. Typically we image 5 mice at the same time. Additional details on bioluminescence imaging were
previously published7.
2. To assess graft success, bioluminescence imaging is performed 1 and 3 days post-grafting. Images are collected from mice oriented in the
same position 10 min after intraperitoneal injection of 2.5 mg D-Luciferin. During imaging, mice are maintained under isoflurane anesthesia5. Representative Results:
Figure 1 illustrates the typical progressive increase in bioluminescence observed 1 to 18 days post-grafting in a properly established orthotopic
xenograft in a nude (NIH III) mouse (A-C). Quantification of the bioluminescence signals observed 1-24 days after grafting shows that, although
these signals progressively increase, tumor growth markedly accelerates in the later stages of the study period (Figure 1D). To rigorously
demonstrate that tumor growth has occurred in grafted mice, we routinely collect the sciatic nerve and, if it appears that tumor has ruptured the
epineurium and invaded adjacent tissue, surrounding soft tissue and skeletal muscle. Given the aggressive growth of MPNSTs, it is not surprising
that we often find that the grafted tumor cells have breached the normal barriers of the nerve and invaded adjacent tissues (Figure 1E). We also
often find that grafted MPNST cells migrate aggressively into nerve proximal and distal to the graft site.
Figure 1. Bioluminescence imaging of NIH III mouse orthotopically grafted with luciferase-tagged MPNST cells 1 day post-grafting (A). Note that
the signals detected within the region of interest (ROI) in different mice are all within one order of magnitude of each other. Reimaging 10 days (B)
and 18 days (C) post-grafting shows that bioluminescent signals progressively increase at the graft site in individual mice. (D) Graph illustrating
the progressive increase in the relative photon counts/second detected over the graft site 1-24 days post-grafting. (E) Photomicrograph of the
graft site from this mouse demonstrating tumor growth and focal invasion into adjacent skeletal muscle.
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and their body temperature kept at 37°C by a heating pad present in the Xenogen imager. Image acquisition times are in the range of 2 sec to
10 min; the data acquisition software insures that no pixels are saturated during image collection. Light emission from tumor regions (relative
photon counts/sec) is measured using proprietary software from Xenogen. Light emission intensity is represented by pseudocolor scaling of
the bioluminescence that is overlayed on black and white photographs of the mice that are collected at the same time.
3. To be eligible for inclusion in a preclinical trial cohort, mice must have a detectable bioluminescence signal both 1 and 3 days post-grafting
and the intensity of the bioluminescence signal must increase between days 1 and 3. Animals that have a decreased or static signal are
excluded. In addition, signals detected in mice grafted on the same day should be within 1 order of magnitude of each other; mice with
bioluminescence signals that are one order of magnitude lower or higher than those detected in animals grafted on the same day are also
excluded.
4. Once mice have been identified that meet these criteria, they must be randomized into treatment groups. To achieve this, luciferase signals
detected in grafted mice 3 days post-grafting are first ordered from highest to lowest intensity. Mice are then randomized into groups by
assigning them in order of intensity to the treatment groups, reversing this order and then repeating the process until all mice are assigned to
groups. For example, if there are 4 treatment groups (e.g., placebo and three concentrations of test drug) mice are assigned to the groups in
the order 1, 2, 3, 4, 4, 3, 2, 1, 1, 2, 3, 4, 4, 3, 2, 1..etc. Before initiating treatment, the bioluminescence signals detected in each member of
the assigned group are averaged to make sure that the average starting signals within all groups are as close as possible. Administration of
the candidate therapeutic agent is begun on day 3.
5. To assess the effect the therapeutic agent has on graft growth during the course of treatment, bioluminescence imaging is performed once a
week after beginning therapy (days 10, 17, 24, 30 post-grafting). For non-nude immunodeficient mice, it is critically important that animals
again have new fur growth removed with Nair prior to performing each imaging session. This is because hair blocks bioluminescent signals,
with coat color determining how much of the signal is lost. For instance, white fur such as is found on Swiss Webster mice produces an 18%
reduction in bioluminescent signal intensity8, while black fur can decrease signals as much as 10-fold9. We would also note that it cannot be
assumed that uniform fur regrowth will occur in all treatment groups and "normalize" signal reductions among the treatment groups. This is
because the therapeutic agent itself may affect hair growth. For instance, we have noted that tamoxifen treatment inhibits hair regrowth,
thereby minimizing the perceived effect of this agent on tumor growth when compared to placebo-treated mice.
6. With ST88-14 MPNST cells, mice can be carried for 30 days post-grafting. At this time, tumors typically have grown to the maximal size
allowed by institutional animal care and use committees and must be sacrificed. Following the final imaging session, mice are killed and
specimens necessary for further analysis of treatment outcomes (e.g., blood for determination of circulating levels of the therapeutic agent,
tumor tissue for weight determination, examination of histology, determination of Ki67 and TUNEL labeling indices and assessment of
biochemical parameters) collected. Precisely what specimens are collected will depend on the needs of the experimental design.
7. Mice with tumors should be monitored daily and terminated if they become ill (lack normal grooming and avoidance behaviors), are unable to
eat or drink, or if the tumor becomes overly large as to hinder normal body movement. Tumor burden should not be allowed to exceed 10% of
the animal's normal body weight. Tumor weight as a percentage of body weight is calculated by comparing the weight of the tumor bearing
animals to the weight of age/sex matched control animals. Cachexia should not be allowed to become clinically significant. Weight loss in
tumor-bearing animals should not exceed 20% of normal body weight.Discussion
The detailed orthotopic xenografting method presented here is one that we developed using ST88-14 MPNST cells, a line which is widely used in
studies of these NF1-associated peripheral nerve sheath tumors. However, this methodology is easily adaptable for preclinical studies with other
MPNST cell lines. For instance, we have also performed orthotopic xenografting with STS-26T10cells, a line derived from a sporadically occurring
MPNST and T265-2c11
cells, which are derived from a NF1-associated MPNST, with success similar to that we observed with ST88-14 cells.
Having said that, we would note that the exact conditions we describe here for orthotopic xenografting of ST88-14 cells cannot be directly
adopted for the grafting of other MPNST lines. Instead, key parameters of the methodology must be empirically determined for each cell line.
These parameters include the number of MPNST cells initially grafted, the time allowed for graft development and, to a lesser extent, the volume
in which the tumor cells are injected. To establish these parameters for a new line, we graft groups of mice (5 mice per group) with 103 to 5 x 106
tumor cells, checking two concentrations of cells for each order of magnitude (i.e., 103 cells, 5 x 103 cells, 104 cells, 5 x 104 cells, etc.). Larger
numbers of tumor cells (>106) must be injected in a larger volume; we have found that up to 5 mL can be injected without loss of cells from the
grafted nerve. We have also found that no more than 5 x 106 tumor cells per 5 mL volume can be injected as denser suspensions become
increasingly prone to shear which kills the tumor cells. We follow these mice until at least three animals within each group have palpable tumors,
at which point we terminate that group and examine the nerve histologically to confirm graft growth. Obviously, the time required to reach this
point will differ, depending on the number of cells injected; in general, we are seeking a concentration of cells that will reach maximal allowable
tumor growth within 30-60 days. More rapid growth can make it difficult to achieve effective therapeutic concentrations prior to termination of the
experiment and/or prevent the collection of sufficient bioluminescence imaging datapoints over the course of the experiments. A time course
longer than 60 days makes adjusting experimental parameters unwieldy and unnecessarily prolongs the duration of the planned experiments.
Finally, we would also note that we have used this orthotopic xenografting methodology with ST88-14 cells grafted into NIH III mice to
demonstrate the therapeutic effectiveness of tamoxifen6. A detailed description of the methods we routinely use to assess the effects of candidate
therapeutic agents on orthotopic xenografts can be found in that manuscript. It has also been demonstrated that neurofibroma cells can be
successfully grafted into peripheral nerve12, suggesting that, with modifications, the procedures outlined in this protocol can be used to perform
preclinical trials with candidate therapeutic agents directed against neurofibromas.
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